Welcome back to our “Meet the CN Bio team” blog series, where we are showcasing the unique expertise and talent that makes us who we are. We sat
6 Challenges in ADME Drug Development
When developing drugs, we rely heavily on in vitro, in vivo animal and in silico models to predict how the human body will interact with drugs before
Meet the CN Bio team – Joanna Michalowska
Welcome to our new "Meet the CN Bio team" blog series, where you'll get a behind-the-scenes look at the incredible individuals who make our company
How in vitro human Gut/Liver models increase confidence in ADME estimations before human trials
Imagine a world where developing new medicines is faster, cheaper, and less reliant on the use of animals for testing. Novel multi-organ in vitro
Organ-on-a-chip adoption: The roadmap to broader use
Paving the way for Organ-on-a-chip adoption Drug discovery is becoming more complex as we move from a small molecule world to large molecules and
CN Bio appoints Lydia Seymour as VP People and Culture to further strengthen leadership team
Key appointment to support continued UK and US team expansion CN Bio, a leading provider of single- and multi-organ microphysiological systems,
Global Fatty Liver Day 2024: How Organ-on-a-Chip Addresses R&D Challenges
To commemorate Global Fatty Liver Day on June 13, this article explores how organ-on-a-chip models are transforming liver disease research. Over
Meet the CN Bio team -Dr. Dharaminder Singh
Welcome to our new "Meet the team" blog series, where you'll get a behind-the-scenes look at the incredible individuals who make our company
CN Bio raises $21 million USD in first close of Series B investment round
Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively. Investment will expand product